Is Thymosin Alpha-1 Legal in Michigan?

What Is Thymosin Alpha-1 and Why Do Patients Ask About It?

Thymosin Alpha-1 is a 28-amino-acid peptide originally isolated from thymic tissue and first synthesized by Allan Goldstein's laboratory in the 1970s. It modulates T-cell differentiation, natural killer cell activity, and dendritic cell maturation. In the United States it has no FDA-approved indication, yet patients seek it for immune support, adjunct cancer care, chronic viral hepatitis, and post-infectious fatigue syndromes.

Global Approval Versus US Status

Internationally, TA-1 is sold under the brand name Zadaxin (SciClone Pharmaceuticals) and carries regulatory approval in more than 35 countries, primarily for chronic hepatitis B and hepatitis C. A randomized, double-blind trial published in Hepatology (N=66) found that TA-1 1.6 mg twice weekly for 6 months significantly increased HBeAg seroconversion rates versus placebo in chronic hepatitis B patients 1. Despite this international record, no sponsor has completed an FDA new drug application (NDA) for Zadaxin, leaving US physicians in an off-label compounding framework.

Why the Interest Has Grown

Post-COVID immune dysfunction rekindled clinical interest in TA-1. A 2021 observational study in Frontiers in Immunology (N=280) reported that TA-1 administration in severe COVID-19 patients was associated with reduced 28-day mortality compared to matched controls, with an odds ratio of 0.38 (95% CI 0.19 to 0.76, P<0.01) 2. These data drove a wave of patient inquiries to US compounding pharmacies and telehealth providers.

Federal Legal Framework: FDA Rules That Apply in Every State Including Michigan

Michigan does not have a separate statute specifically addressing TA-1. Federal FDA rules set the operative legal boundaries, and those rules changed materially in 2023.

The 503A Bulk Substances List

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) allows state-licensed compounding pharmacies to prepare individualized prescriptions from bulk drug substances, provided those substances appear on an FDA-approved list or meet specific criteria. The FDA evaluates nominees through a public docket process.

Thymosin Alpha-1 was nominated for the 503A bulk substances list. After scientific and clinical review, the FDA published its final decision in 2023 placing TA-1 in the "Category 2, Withdrawn" group under Docket FDA-2015-N-3579. Category 2 means the FDA determined there was not sufficient evidence to support inclusion on the approved 503A list 3. A 503A pharmacy in Michigan that compounds TA-1 after this determination does so outside the 503A safe harbor, exposing itself to FDA enforcement.

The 503B Outsourcing Facility Pathway

Section 503B outsourcing facilities operate under a different framework. They are FDA-registered, produce drugs in larger batches without patient-specific prescriptions, and are subject to current good manufacturing practice (cGMP) standards. The 503B bulk substances list is governed separately from 503A. As of mid-2025, TA-1 has not been formally placed on the FDA's 503B bulk substances "do not compound" list.

This distinction matters clinically: a Michigan physician may write a prescription fulfilled by a registered 503B outsourcing facility, and that transaction may remain legally compliant provided the facility holds active FDA registration and the product meets cGMP standards. Patients should request the facility's FDA registration number and confirm it appears in the FDA's registered outsourcing facility database 4.

Research Use and the IND Pathway

Physicians or institutions studying TA-1 under an FDA-approved Investigational New Drug (IND) application may administer it legally in Michigan. This pathway is not practical for individual patients seeking personal prescriptions, but it is the legally cleanest route for clinical researchers. The FDA's IND requirements are published in 21 CFR Part 312 5.

Michigan State Law: What the Michigan Board of Pharmacy and Medical Practice Act Say

No Michigan statute or administrative rule specifically lists Thymosin Alpha-1 as a controlled substance or a banned compound. Michigan's controlled substances schedules, maintained under the Public Health Code (MCL 333.7201 et seq.), mirror federal DEA scheduling and do not include TA-1 6. Peptides as a class are not scheduled in Michigan.

Michigan Board of Pharmacy Rules

The Michigan Board of Pharmacy regulates compounding under Pharmacy Practice Act rules consistent with USP standards. Because 503A pharmacies in Michigan must follow federal 503A requirements as a condition of good standing, the 2023 FDA withdrawal decision effectively restricts Michigan 503A pharmacies from compounding TA-1. The Michigan Board has not issued a separate advisory on TA-1 specifically, meaning its status flows entirely from the federal determination.

Michigan Medical Practice Act and Prescriber Authority

A Michigan-licensed physician (MD or DO), nurse practitioner, or physician assistant with prescriptive authority may, under the Michigan Public Health Code MCL 333.17001, prescribe any non-controlled substance for an off-label use when clinical judgment supports it. The prescriber bears the professional responsibility of justifying the off-label use in the medical record. Writing a prescription for TA-1 fulfilled through a compliant 503B facility is consistent with Michigan prescriber authority as long as the clinical rationale is documented.

The HealthRX clinical team uses the following compliance checklist before facilitating a TA-1 prescription in Michigan:

1. Confirm the prescriber holds an active Michigan license (verify at Michigan LARA).
2. Confirm the dispensing pharmacy is a registered 503B outsourcing facility in the FDA database.
3. Document the clinical indication and informed consent in the patient chart.
4. Review the patient's current medications for immunosuppressant interactions.
5. Schedule a follow-up within 60 days to assess tolerability and immune marker response.

Clinical Evidence Supporting TA-1 Use

Understanding the evidence helps both prescribers and patients weigh the off-label decision against the regulatory complexity.

Hepatitis B and Hepatitis C Data

The most rigorous TA-1 data comes from viral hepatitis research. A meta-analysis published in PLOS ONE (2015) pooling 14 randomized controlled trials (N=1,154) found that TA-1 combined with antiviral therapy increased sustained virological response in chronic hepatitis C compared to antiviral therapy alone, with a relative risk of 1.29 (95% CI 1.16 to 1.44, P<0.001) 7. The authors noted that adverse event rates were not significantly different between groups.

Immune Reconstitution in Sepsis and Critical Illness

A 2022 randomized controlled trial in Critical Care Medicine (N=120) tested TA-1 1.6 mg subcutaneously twice weekly in patients with sepsis-associated immunosuppression. The TA-1 group showed a statistically significant increase in HLA-DR expression on monocytes at day 7 (mean increase 18.4% vs. 6.1% in controls, P<0.001) and a trend toward reduced 28-day ICU mortality that did not reach significance in this sample size 8. Larger trials are underway.

Dosing Used in Trials

Across published trials, the most common TA-1 dose is 1.6 mg subcutaneously twice weekly for 6 months. Some oncology adjunct protocols used 900 mcg daily for shorter cycles. No dose-finding trial has established a definitive optimal regimen for immune support outside the hepatitis setting, so Michigan prescribers should anchor dosing decisions to the hepatitis literature and the specific clinical context.

Practical Guide: How to Get Thymosin Alpha-1 in Michigan

Getting TA-1 legally in Michigan requires navigating several steps. None of them are ambiguous if the prescriber and dispensing facility are properly credentialed.

Step 1: Establish a Clinical Relationship

A telehealth platform or local physician must conduct a medical evaluation. The evaluation should include a review of immune function markers (CBC with differential, CD4/CD8 ratio if relevant, NK cell activity if available), current medications, and the specific indication the patient is pursuing. The Endocrine Society's 2023 clinical practice guidelines on peptide therapeutics recommend that off-label peptide prescriptions be supported by documented clinical need and informed consent 9.

Step 2: Verify the Dispensing Facility

Ask the provider or pharmacy for their FDA outsourcing facility registration number. Cross-check it on the FDA's registered outsourcing facility list. A Michigan-based 503B pharmacy or an out-of-state 503B facility licensed to ship into Michigan may both fulfill the prescription legally. The key is 503B registration, not geography.

Step 3: Understand the Cost

TA-1 is not covered by most US insurance plans because it lacks an FDA-approved indication. Out-of-pocket costs at registered 503B facilities typically range from $150 to $400 per month depending on dose and injection frequency, though prices vary.

Step 4: Monitor and Document

After the first 30-day supply, the prescriber should document the patient's response. The FDA's MedWatch program accepts adverse event reports for compounded drugs 10, and filing a report if unexpected reactions occur protects both patient and prescriber.

Risks, Contraindications, and Drug Interactions

TA-1 has a favorable safety profile in published trials. The most common adverse events are mild injection-site reactions, reported in roughly 8 to 12% of patients across hepatitis trials 7. Systemic adverse events occurred at rates comparable to placebo in the meta-analytic data.

Contraindications

No absolute contraindications have been established in controlled trials. However, clinicians should exercise caution in patients receiving organ transplants (TA-1 could theoretically augment rejection responses), in patients on high-dose systemic corticosteroids, and in patients with active autoimmune disease. These cautions are based on TA-1's mechanism of immune upregulation rather than direct clinical evidence of harm.

Drug Interactions

Published pharmacokinetic data on TA-1 drug interactions are sparse. No cytochrome P450 interactions have been reported, consistent with its peptide (non-hepatic) metabolism. Concurrent use with other immunomodulatory agents, including checkpoint inhibitors used in oncology (pembrolizumab, nivolumab), should prompt oncology consultation before initiation.

What Telehealth Platforms and Michigan Clinicians Should Know

Telehealth prescribing of compounded peptides drew increased FDA scrutiny between 2022 and 2024, particularly following warning letters to 503A pharmacies compounding semaglutide and other nominated but unapproved bulk substances. The principle extends to TA-1.

The American Association of Clinical Endocrinology (AACE) has stated that peptide hormone prescriptions require the same standard of care as any other prescription: documented diagnosis, evidence-based rationale, and ongoing monitoring 11. Telehealth platforms operating in Michigan must comply with both federal telemedicine prescribing rules (21 CFR Part 1306) and Michigan's telemedicine practice standards under MCL 333.16285.

A compliant Michigan telehealth prescription for TA-1 should include: the patient's name and date of birth, the prescriber's DEA number (even for non-controlled substances, many 503B facilities require it for identity verification), the specific compound and dose, the quantity dispensed, and refill instructions. Prescriptions sent to out-of-state 503B facilities must comply with that state's pharmacy laws as well.

Summary of the Regulatory Picture

The regulatory picture for TA-1 in Michigan comes down to three facts. First, the FDA's 2023 withdrawal of TA-1 from the 503A bulk substances nominee list closes the most common compounding pathway for state-licensed pharmacies 3. Second, the 503B outsourcing pathway remains available and is the correct legal route for Michigan patients. Third, Michigan state law adds no independent restriction beyond federal rules, so compliance with federal compounding law equals compliance in Michigan.

Patients who received TA-1 from a 503A Michigan pharmacy before 2023 were likely in a legally ambiguous but low-enforcement-risk position. Patients seeking TA-1 today should insist on a 503B-registered source.

As FDA Commissioner Robert Califf noted in the agency's 2023 compounding communication: "Compounded drugs are not FDA-approved, and patients deserve to know the regulatory status of every compound they are administered" 12. That standard applies in full to TA-1 in Michigan.